Latest Jing Li News
Oct 1, 2020
Yang Li,1 Jing Li,2 Zirong Liu,1 Yamin Zhang1 1Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin 300192, People’s Republic of China; 2Department of Gynaecology, Tianjin First Central Hospital, Tianjin 300192, People’s Republic of China Correspondence: Yamin Zhang Department of Hepatobiliary Surgery Tianjin First Central Hospital, Tianjin 300192, People’s Republic of China Email firstname.lastname@example.org Background/Aims: To analyze the clinical significance of miR-196b expression in ovarian cancer and predict the function and possible mechanism of miR-196b. Methods: Both Kaplan–Meier (K-M) and Cox proportional hazards regression model were used to analyze the prognostic factors of patients with ovarian cancer. MiR196-b was modulated in ovarian cancer cells, and the cell viability, cell cycle, and cell cycle-related gene expression were analyzed. The target genes of miR-196b were then predicted and checked the relationship between the target genes. Results: MiR-196b was an independent risk factor, while high expression of miR-196b was associated with poor prognosis of ovarian cancer. MiR-196b overexpression increased cancer cell proliferation. Cdkn1b, as one of the targets of miR-196b, was related to cell viability and mitosis. Conclusion: High expression of miR-196b was significantly associated with poor prognosis of the patients with ovarian cancer. MiR-196b could increase the cell proliferation of ovarian cancer by modulating Cdkn1b expression. Keywords: microRNAs, MiR-196b, ovarian cancer, Cdkn1b, proliferation This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License . By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .